Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Mar 6, 2009

Premium

Fate Therapeutics announced this week that Dan Shoemaker has been named chief technology officer.

Shoemaker was most recently chief scientific officer of ICx Biosystems. From 2003 to 2005, he was chief scientific officer of GHC Technologies, where he led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Shoemaker held several positions at Merck Research Laboratories, including director of target discovery, senior director at Rosetta Inpharmatics, and research fellow in the department of molecular neurosciences.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.